Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Instituto Mixto Universitario Deporte y Salud (iMUDS) | UNKNOWN |
| Research Center for Mind, Brain and Behavior, Spain | OTHER |
| University Hospital Virgen de las Nieves | OTHER |
Not provided
Not provided
Not provided
Not provided
The Heart-Brain project is a randomized controlled trial designed to examine the effects of two different exercise programs of 12-week duration: 1) aerobic high intensity interval training (HIIT), and 2) aerobic HIIT plus resistance training, on brain health and other outcomes in coronary heart disease patients.
Patients with coronary heart disease (CHD) has higher risk of developing dementia, cognitive impairment, and mental disorders. There is, therefore, a need to identify effective and sustainable initiatives to avoid or attenuate cognitive and mental health declines in these patients, and in this context, physical exercise can play a major role. The overall objective of the present project is to investigate the effects of exercise on brain health outcomes in CHD patients. The Heart-Brain project is a single-blinded, exercise-based randomized controlled trial. We will run a three-arms trial with a waiting-list control group, and two intervention groups that will receive two different supervised exercise programs: 1) aerobic high intensity interval training (HIIT) and 2) a combination of aerobic HIIT plus resistance training. The study will be conducted in 90 patients with CHD who meet the eligibility criteria indicated below.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| 12-week of aerobic high-intensity interval training (HIIT) exercise program | Experimental |
| |
| 12-week aerobic HIIT plus resistance exercise program | Experimental |
| |
| Usual care, Wait-list control group | No Intervention | The control group (as well as the 2 intervention groups) will be treated as usual in outpatient Phase III, which in Spain includes periodic medical revisions and medication control. In addition, for the control group, we will apply the wait-list strategy providing the supervised exercise program once all data collection for pre- and post-intervention assessment points have been finished. |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Two types of exercise interventions | Behavioral |
|
| Measure | Description | Time Frame |
|---|---|---|
| Change in cerebral blood flow | The main outcome is the change in global cerebral blood flow from baseline to 12 weeks. Cerebral blood flow will be measured using the magnetic resonance imaging technique of TGSE-pCASL (turbo gradient spin echo-pseudo continuous arterial spin labeling). Additionally, regional cerebral blood flow will be determined in a voxel-wise analysis to measure local perfusion. | Baseline and 12 weeks |
| Measure | Description | Time Frame |
|---|---|---|
| Change cerebral vascularization | Cerebral vascularization will be measured using the magnetic resonance angiography TOF (Time-of-flight angiography). | Baseline and 12 weeks |
| Change in executive function and general cognition |
| Measure | Description | Time Frame |
|---|---|---|
| Change in blood brain barrier (BBB) permeability | BBB permeability will be operationally measured by using a recently developed neuroimaging technique that measures water exchange across the BBB using 3D diffusion-prepared arterial spin labelled perfusion MRI. | Baseline and 12 weeks |
| Change in brain morphology |
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Francisco B Ortega, Professor | Department of Physical Education and Sports, Faculty of Sport Sciences, University of Granada, Spain | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Sport and Health University Research Institute (iMUDS), Technological Health Park, University of Granada | Granada | 18007 | Spain |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 39246594 | Background | Toval A, Solis-Urra P, Bakker EA, Sanchez-Aranda L, Fernandez-Ortega J, Prieto C, Alonso-Cuenca RM, Gonzalez-Garcia A, Martin-Fuentes I, Fernandez-Gamez B, Olvera-Rojas M, Coca-Pulido A, Bellon D, Sclafani A, Sanchez-Martinez J, Rivera-Lopez R, Herrera-Gomez N, Penafiel-Burkhardt R, Lopez-Espinosa V, Corpas-Perez S, Garcia-Ortega MB, Vega-Cordoba A, Barranco-Moreno EJ, Morales-Navarro FJ, Nieves R, Caro-Rus A, Amaro-Gahete FJ, Mora-Gonzalez J, Vidal-Almela S, Carlen A, Migueles JH, Erickson KI, Moreno-Escobar E, Garcia-Orta R, Esteban-Cornejo I, Ortega FB. Exercise and brain health in patients with coronary artery disease: study protocol for the HEART-BRAIN randomized controlled trial. Front Aging Neurosci. 2024 Aug 23;16:1437567. doi: 10.3389/fnagi.2024.1437567. eCollection 2024. | |
| 39809303 |
Not provided
Not provided
The protocol, statistical analyses plan and data management plan will be share open access. Data files including IPD, and corresponding data dictionaries, will be shared under restricted access and upon reasonable request (contact FB Ortega) due to privacy issue and GDPR regulations. In principle, all collected IPD will be available for sharing under the "as open as possible, as closed as necessary" principle. The shared data files will be pseudonymized, only include participants who provided informed consent for sharing, and sharing is only possible when the data is used for research purposes regarding exercise, and cardiovascular and brain health. This is stated at the informed consent files that the participants signed when they agree to participate
The IPD data will be available 12 months after the primary outcome paper published. The data will be available 15 years after data collection.
The specific process of data access will be determined in a later stage, but in general the research team supports data sharing. Roughly, data will be available upon reasonable request to the PI (FB Ortega). The data requests must contain the purpose and aim of the research, but also specification of the data requested, and data analysis before data sharing. Data will only be shared for research purposes on exercise, cardiovascular and brain health. In addition, we will follow "as open as possible, as closed as necessary" principle, so depending on this principle we will decide whether the data could be shared. A data access committee will be installed to approve data requests.
Not provided
Not provided
| Type | Includes Protocol | Includes SAP | Includes ICF | Document Label | Document Date | Document Uploaded Date | Document File Name |
|---|---|---|---|---|---|---|---|
| Prot | Yes | No | No | Study Protocol | Jan 29, 2024 | Jan 30, 2024 | Prot_000.pdf |
| SAP | No | Yes | No | Statistical Analysis Plan | Jan 29, 2024 | Jan 30, 2024 | SAP_001.pdf |
Not provided
| ID | Term |
|---|---|
| D003327 | Coronary Disease |
| D003324 | Coronary Artery Disease |
| D017202 | Myocardial Ischemia |
| D009043 | Motor Activity |
| ID | Term |
|---|---|
| D006331 | Heart Diseases |
| D002318 | Cardiovascular Diseases |
| D014652 | Vascular Diseases |
| D001161 | Arteriosclerosis |
Not provided
Not provided
| Hospital Clinico Universitario San Cecilio |
| OTHER |
| Centro de Investigación Biomédica en Red de Fisiopatología de la Obesidad y Nutrición | OTHER |
Not provided
Not provided
Not provided
Not provided
|
A comprehensive neuropsychological battery will assess several domains of executive function: working memory, cognitive flexibility and inhibitory control, and an executive function score will be computed and used as main behavioral outcome . Additionally, the general cognition will be assessed by the MOCA (MONTREAL COGNITIVE ASSESSMENT) test.
| Baseline and 12 weeks |
| Change in cardiorespiratory fitness | Cardiorespiratory fitness will be assessed by a cardiorespiratory exercise test in a treadmill measuring gas exchange (treadmill time-to-exhaustion and VO2peak) | Baseline and 12 weeks |
MRI (magnetic resonance imaging) will measure brain morphology including volume, area, cortical thickness, and shapes by a T1-weighted MPRAGE structural sequence. |
| Baseline and 12 weeks |
| Change in white matter structure | MRI (magnetic resonance imaging) will measure white matter structure and lesions by diffusion weighted acquisition sequence. | Baseline and 12 weeks |
| Change in brain function | MRI (magnetic resonance imaging) will measure brain function during resting state. Measures of brain activity and brain connectivity will be calculated. | Baseline and 12 weeks |
| Change in blood-based neurology biomarkers | Blood samples will be used to determine plasmatic concentration of peripheral neurology biomarkers including brain-derived neurotrophic factor (BDNF), vascular endothelial growth factor (VEGF) and cathepsin B (CTSB), as well as novel neurodegenerative biomarkers based on new evidence up to the time of the analysis. | Baseline and 12 weeks |
| Change in saliva-based neurology biomarkers | Saliva samples will be used to determine concentration of peripheral neurology biomarkers including brain-derived neurotrophic factor (BDNF), vascular endothelial growth factor (VEGF) and cathepsin B (CTSB), as well as novel neurodegenerative biomarkers based on new evidence up to the time of the analysis. | Baseline and 12 weeks |
| Hemodynamic vascular changes | Hemodynamic vascular parameters will be measured using ultrasound echography (i.e. carotid intima-media thickness). | Baseline and 12 weeks |
| Hemodynamic cardiac changes | Cardiac parameters will be measured using ultrasound echography (i.e. ejection fraction, cardiac volumes, and cardiac output) | Baseline and 12 weeks |
| Hemodynamic transcranial changes | Hemodynamic transcranial parameters will be measured using ultrasound echography (i.e. Doppler diastolic-systolic velocity). | Baseline and 12 weeks |
| Change in general muscular strength | The maximum isometric strength of the hand and forearm muscles measured with the handgrip test (Kg) will be used to determine general muscular strength. | Baseline and 12 weeks |
| Change in lower body muscular strength | Muscular strength in lower body will be assessed using the chair stand test (number of repetitions). | Baseline and 12 weeks |
| Change in upper body muscular strength | Muscular strength in upper body will be assessed using the arm curl test (number of repetitions). | Baseline and 12 weeks |
| Change in physical function | Senior Fitness Test (including the 6-min walking test) will assess overall physical functioning and z-scores will be calculated. | Baseline and 12 weeks |
| Change in depression | Depressive symptoms will be assessed using the Global Deterioration Scale, the Health Survey Short Form (SF-36) and the Hospital Anxiety and Depression Scale. | Baseline and 12 weeks |
| Change in anxiety | Anxiety will be assessed using the Health Survey Short Form (SF-36) and the Hospital Anxiety and Depression Scale. | Baseline and 12 weeks |
| Change in stress outcomes | Stress outcomes will be assessed using the Perceived Stress Scale. | Baseline and 12 weeks |
| Change in loneliness | Loneliness will be assessed using the UCLA Loneliness Scale. | Baseline and 12 weeks |
| Change in self-esteem outcomes | Self-esteem will be assessed using the Rosenberg Self-Esteem Scale. | Baseline and 12 weeks |
| Change in social support outcomes | Social support will be assessed using the Social Provisions Scale. | Baseline and 12 weeks |
| Change in health-related quality of life | Global, physical, and mental health-related quality of life will be self-reported using the Health Survey Short Form (SF-36), in which higher scores means a better health-related quality of life. | Baseline and 12 weeks |
| Change in physical activity | Physical activity will be measured using the accelerometer Axivity AX, and a self-reported questionnaire based on the Global Physical Activity Questionnaire. | Baseline and 12 weeks |
| Change in sedentary behaviors | Sedentary behaviors will be measured using the accelerometer Axivity AX, and a self-reported questionnaire based on the Global Physical Activity Questionnaire. | Baseline and 12 weeks |
| Change in sleep quality | Sleep quality will be measured using the accelerometer Axivity AX, and using the Pittsburgh Sleep Quality Index. | Baseline and 12 weeks |
| Change in diet behaviors | Diet behaviors will be self-reported using the 14-item Questionnaire of Mediterranean Diet Adherence (PREDIMED-14), and a self-reported question for supplements intake. | Baseline and 12 weeks |
| Change in body mass index | Body mass index (BMI) will be assessed using a dual-energy x-ray absorptiometer (DXA) and a TANITA's Bioelectrical Impedance Analysis. Weight and height will be combined to report BMI in kg/m^2 | Baseline and 12 weeks |
| Change in lean mass | Lean mass (kg) will be assessed using a dual-energy x-ray absorptiometer (DXA) and a TANITA's Bioelectrical Impedance Analysis. | Baseline and 12 weeks |
| Change in fat mass | Fat mass (kg) will be assessed using a dual-energy x-ray absorptiometer (DXA) and a TANITA's Bioelectrical Impedance Analysis. | Baseline and 12 weeks |
| Change in bone mineral content and density | Bone mineral content and density (z-score) will be assessed using a dual-energy x-ray absorptiometer (DXA). | Baseline and 12 weeks |
| Change in blood pressure | Systolic and diastolic blood pressure will be assessed by a blood pressure monitor. Central blood pressure will be also analyzed using the SphygmoCor XCEL | Baseline and 12 weeks |
| Change in arterial stiffness | Arterial stiffness will be assessed using the pulse wave analysis and pulse wave velocity determined by the SphygmoCor XCEL | Baseline and 12 weeks |
| Change in blood-based inflammatory biomarkers | Blood samples will be used to determine plasmatic concentrations of inflammatory peripheral biomarkers including tumor necrosis factor-alpha (TNF-alpha) and interleukin-1 beta (IL-1beta), glucose, insulin, HDL and LDL cholesterol. | Baseline and 12 weeks |
| Change in saliva-based inflammatory biomarkers | Saliva samples will be used to determine saliva concentrations of inflammatory peripheral biomarkers including tumor necrosis factor-alpha (TNF-alpha) and interleukin-1 beta (IL-1beta). | Baseline and 12 weeks |
| Change in blood-based cardiovascular biomarkers | Blood samples will be used to determine plasmatic concentrations of cardiovascular peripheral biomarkers including glucose, insulin, HDL and LDL cholesterol. | Baseline and 12 weeks |
| Change in saliva-based cardiovascular biomarkers | Saliva samples will be used to determine plasmatic concentrations of cardiovascular peripheral biomarkers including glucose, insulin, HDL and LDL cholesterol. | Baseline and 12 weeks |
| Change in epigenetics | Blood samples will be stored for epigenetic analyses. | Baseline and 12 weeks |
| Change in gene expression | Blood samples will be stored for genetic analyses, including APOE and BDNF genotypes. | Baseline and 12 weeks |
| Change in oral and gut microbiota | Saliva and fecal samples will be used to determine oral and gut microbiota including the most representative phyla (i.e., firmicutes, bacteroidetes, and proteobacteria) | Baseline and 12 weeks |
| Background |
| Toval A, Bakker EA, Granada-Maia JB, Nunez de Arenas-Arroyo S, Solis-Urra P, Eijsvogels TMH, Esteban-Cornejo I, Martinez-Vizcaino V, Ortega FB. Exercise type and settings, quality of life, and mental health in coronary artery disease: a network meta-analysis. Eur Heart J. 2025 Jun 16;46(23):2186-2201. doi: 10.1093/eurheartj/ehae870. |
| D001157 |
| Arterial Occlusive Diseases |
| D001519 | Behavior |